OakChart

Arcutis Biotherapeutics Inc

ARQTHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 11:15 AM ET

28.19+0.81 (2.94%)
2026-11-11 17:15 CET
Market cap
3,462.97 USD m
Revenue, TTM
508.68 USD m
Net income, TTM
29.91 USD m
Free cash flow, TTM
59.71 USD m
EPS diluted, TTM
0.22
P/E
130.69
Compare

Price

ARQT against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.0035.009.6M19.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARQTclose 28.1920-day 30.4350-day 27.37200-day 25.3528.1952w high52w low

19.0% under the 52-week high of 34.80 on 4 Nov 2026. 52-week low 19.30 on 19 May 2026. Last 15 sessions, 37.9% high to low

Profile

ARQT
52-week range, 57% of the way up
19.3034.80

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

IndexRUT
Employees354
IPOJan 31, 2020
Beta1.66
ATR, 14d1.80
Rel volume0.77
Short float16.48%
Insider own12.88%
Inst own97.07%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.56B
Enterprise Value3.43B
Income29.91M
Sales508.68M
Book/sh1.94
Cash/sh2.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees354
IPOJan 31, 2020

Ratios

P/E130.69
Forward P/E26.88
PEG-
P/S7.01
P/B14.56
P/C13.72
P/FCF59.70
EV/EBITDA89.97
EV/Sales6.74
Quick Ratio2.66
Current Ratio2.92
Debt/Eq0.51
LT Debt/Eq0.44
Option/ShortYes / Yes

Earnings

EPS (ttm)0.22
EPS next Y1.05
EPS next Q0.20
EPS this Y312.09%
EPS next Y280.38%
EPS next 5Y-
EPS past 3/5Y71.80% 49.34%
Sales past 3/5Y367.27% -
EPS Y/Y TTM165.45%
Sales Y/Y TTM60.00%
EPS Q/Q15.23%
Sales Q/Q45.05%
EarningsNov 04 AMC
EPS/Sales Surpr.-66.67% 0.93%

Ownership

Insider Own12.88%
Insider Trans-0.92%
Inst Own97.07%
Inst Trans5.37%
ROA6.68%
ROE14.88%
ROIC8.51%
Gross Margin91.18%
Oper. Margin6.91%
Profit Margin5.88%
SMA20-7.35%
SMA503.00%
SMA20011.18%
Trades-

Technical

Shs Outstand126.02M
Shs Float110.17M
Short Float16.48%
Short Ratio7.00
Short Interest18.16M
52W High34.80 -18.99%
52W Low19.30 46.10%
Volatility8.49% 5.50%
ATR (14)1.80
RSI (14)47.70
Beta1.66
Rel Volume0.77
Avg Volume2.59M
Volume607,696

Performance

Perf Week-17.21%
Perf Month8.05%
Perf Quarter9.14%
Perf Half Y29.97%
Perf YTD-2.93%
Perf Year17.31%
Perf 3Y1379.79%
Perf 5Y32.72%
Perf 10Y-
Recom1.25
Target Price40.38
Prev Close27.39
Price28.19
Change %2.94%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedCCantor FitzgeraldOverweight$48+70.3%
Jul 25, 2025InitiatedGGoldmanNeutral$18-36.1%
Dec 30, 2024InitiatedHH.C. WainwrightBuy$19-32.6%
Aug 28, 2024InitiatedJJefferiesBuy$15-46.8%
Jan 03, 2024UpgradeMMizuhoNeutral → Buy$4 → $8-71.6%
Oct 26, 2023DowngradeMMizuhoBuy → Neutral$57 → $4-85.8%
Oct 13, 2023DowngradeGGoldmanBuy → Neutral$32 → $6-78.7%
Sep 07, 2022InitiatedNNeedhamBuy$46+63.2%
Mar 17, 2022InitiatedGGoldmanBuy$45+59.6%
Jun 30, 2021InitiatedMMizuhoBuy$58+105.7%

Peers

Mkt cap
TickerCompanyMkt cap
INCYIncyte Corp24.76B
OGNOrganon & Co3.64B
ORKAOruka Therapeutics Inc7.35B
KRYSKrystal Biotech Inc9.10B
MANEVeradermics Inc6.30B
EVMNEvommune Inc317.01M
SLGLSol-Gel Technologies Ltd209.06M
ALMSAlumis Inc879.07M
DERMJourney Medical Corp125.60M
VRCAVerrica Pharmaceuticals Inc63.39M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Matsuda MasaruEVP, Chief Legal OfficerNov 04 '26Option Exercise3.6440,000145,600151,289Nov 04 06:38 PM
Matsuda MasaruEVP, Chief Legal OfficerNov 04 '26Sale34.3240,0001,372,672111,289Nov 04 06:38 PM
Matsuda MasaruEVP, Chief Legal OfficerNov 02 '26Sale31.861,21938,841111,289Nov 04 06:38 PM
Burnett PatrickEVP, Chief Medical OfficerNov 02 '26Sale31.8694330,047116,649Nov 04 06:38 PM
Watanabe ToddSee RemarksNov 02 '26Sale31.864,377139,466712,826Nov 04 06:38 PM
Masaru MatsudaOfficerNov 04 '26Proposed Sale34.3240,0001,372,670Nov 04 05:16 PM
Todd Franklin WatanabeOfficerNov 02 '26Proposed Sale31.864,377139,466Nov 02 05:29 PM
Masaru MatsudaOfficerNov 02 '26Proposed Sale31.861,21938,841Nov 02 05:27 PM
Patrick BurnettOfficerNov 02 '26Proposed Sale31.8694330,047Nov 02 05:27 PM
Larry Todd EdwardsFormer OfficerOct 20 '26Proposed Sale33.0060,3761,992,408Oct 20 04:53 PM
Welgus Howard G.DirectorOct 15 '26Option Exercise7.934,09432,45939,935Oct 19 04:49 PM
Welgus Howard G.DirectorOct 15 '26Sale26.934,728127,32535,207Oct 19 04:49 PM
Howard WelgusDirectorOct 15 '26Proposed Sale26.934,728127,325Oct 15 03:56 PM
Matsuda MasaruSee RemarksSep 16 '26Sale25.003,67491,853112,508Sep 18 04:17 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
PINKSimplify Health Care ETFAUM: 350.61M
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
IBBiShares Biotechnology ETFAUM: 11.36B

News

latest 14 of 206
  • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.37%
  • Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis (GlobeNewswire) -20.70%
  • Arcutis Misses Badly On Earnings As A Spending Surge Overshadows A ZORYVE Revenue Beat And Higher Guidance (Earnings Whispers) +6.41%
  • Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Arcutis Appoints Rob Scott, MD to Board of Directors (GlobeNewswire)
  • Loading…
  • Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
  • Arcutis Must Prove Zoryve Volume Can Carry Growth As Pricing Tailwind Fades (Earnings Whispers)
  • Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 (GlobeNewswire)
  • Arcutis Presents ZORYVE (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical (GlobeNewswire) +8.53%
  • Arcutis' ZORYVE (roflumilast) Wins 2026 Marie Claire Beauty Award (GlobeNewswire)
  • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options (GlobeNewswire)
  • Heres What Arcutis CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% (TIKR)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.0600.1800.060143.92142.598
2026Q22026-08-050.1100.0550.110129.86118.858
2026Q12026-05-06-0.090-0.064-0.087105.4103.688
2025Q42026-02-250.1300.0920.128129.5113.068
2025Q32025-10-280.060-0.0940.05699.2286.978
2025Q22025-08-06-0.130-0.145-0.12581.5073.698
2025Q12025-05-06-0.200-0.211-0.19965.8562.237
2024Q42025-02-25-0.090-0.256-0.08671.3660.798
2024Q32024-11-06-0.330-0.417-0.33444.7637.627
2024Q22024-08-14-0.420-0.517-0.42430.8629.096
2024Q12024-05-14-0.320-0.685-0.31949.5715.184
2023Q42024-02-27-0.720-0.782-0.71613.5311.417
2023Q32023-11-03-0.730-0.914-0.72538.1132.918
2023Q22023-08-08-1.160-1.250-1.1565.194.608
2023Q12023-05-09-1.310-1.285-1.3102.803.149
2022Q42023-02-28-1.180-1.423-1.1812.962.209

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-22.780-22.380-1.1030.000.00
2020FY-3.800-3.880-3.8040.000.00
2021FY-4.180-4.209-4.1770.000.00
2022FY-5.660-5.932-5.6603.692.97
2023FY-3.780-3.918-3.78259.6157.58
2024FY-1.160-1.323-1.158196.54185.46
2025FY-0.130-0.185-0.130376.07360.26
2026FY-0.276--542.15
2027FY-1.049--703.01
2028FY-1.833--853.77
2029FY-2.450--1,011
2030FY-2.945--1,163

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06751163.07160.9165.1
2026Q4S2026-11-05751163.07160.9165.1
2026Q4S2026-11-04710160.67156.83167.43
2026Q4S2026-10-20710160.67156.83167.43
2026Q4S2026-10-16760160.67156.83167.43
2026Q4S2026-10-14760159.82153.6167.43
2026Q4S2026-10-06660160.31153.6167.43
2026Q4S2026-09-14660160.15153.6167.43
2026Q4S2026-08-10770160.41153.6167.43
2026Q4S2026-08-06770160.41153.6167.43
2026Q4S2026-07-21710146.15138.7149.73
2026Q4S2026-07-14723146.15138.7149.73
2026Q4S2026-07-07723146.2138.7149.73
2026Q4S2026-06-29713145.41138.7149.73

Estimate history

EPS, annual-0.137-0.531-1.103-3.804-4.177-5.66-3.782-1.158-0.1270.2157
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.334-0.086-0.199-0.1250.0560.128-0.0870.110.064
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000003.68659.606196.542376.072508.68
Period201720182019202020212022202320242025TTM
Sales, quarterly44.75571.3665.84681.50499.219129.503105.398129.861143.919
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual36.23636.23638.08943.33850.25661.03796.787117.848123.333126.018
Period201720182019202020212022202320242025MRQ
Shares, quarterly116.999117.848119.138119.798120.288123.333125.042125.591126.018
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue508.68376.07196.5459.613.690.000.000.000.00
Cost of Goods Sold Incl. D&A44.8736.7019.136.121.700.760.460.200.00
Gross Profit463.81339.38177.4153.491.99-0.76-0.46-0.200.00
Selling, General and Administrative Excl. Other428.65351.60305.81294.59303.62205.77136.1942.9419.73
Research and Development93.8677.0576.42110.58182.44145.56115.3136.5217.94
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income35.16-12.23-128.40-241.10-301.63-206.53-136.65-43.13-19.73
Interest Expense13.7312.0827.1729.7115.65-0.000.000.00
Unusual Expense0.07-0.14-0.280.000.000.000.00--0.07
Net Income Before Taxes30.80-14.97-139.39-259.03-311.46-206.36-135.68-42.00-19.25
Income Taxes0.891.170.653.110.000.000.000.000.00
Consolidated Net Income29.91-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.25
Net Income From Continuing Operations29.91-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.25
Net Income29.91-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.25
EPS (Recurring)0.22-0.13-1.16-3.78-5.66-4.18-3.80-1.10-0.53
EPS (Basic, Before Extraordinaries)0.23-0.13-1.16-3.78-5.66-4.18-3.80-1.10-0.53
EPS (Diluted)0.22-0.13-1.16-3.78-5.66-4.18-3.80-1.10-0.53
EBITDA38.11-6.86-125.80-239.22-300.37-205.77-136.19-42.94-19.73
Non-Operating Income (Expense)9.459.2015.8911.795.820.170.971.140.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense36.2431.8932.9730.6632.6823.897.940.820.15
Price To Earnings Ratio126.96126.96-------
Price To Sales Ratio7.119.828.573.76220.97----
Gross Margin91.1890.2490.2789.7454.02----
Operating Margin6.91-3.25-65.33-404.49-8,183.04----
Net Margin5.88-4.29-71.25-439.79-8,449.76----
Shares Outstanding126.02123.33117.8596.7961.0450.2643.3438.0936.24
Market Capitalization3,462.973,462.971,630.44304.85901.731,043.121,227.441,278.49-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue143.92129.86105.40129.5099.2281.5065.8571.36
Cost of Goods Sold Incl. D&A12.4610.949.7811.698.697.498.836.91
Gross Profit131.46118.9295.61117.8190.5374.0157.0264.45
Selling, General and Administrative Excl. Other122.02102.49104.7099.4382.0188.6281.5572.09
Research and Development22.4220.3630.6320.4519.6019.4517.5414.48
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income9.4416.43-9.0918.398.53-14.61-24.53-7.63
Interest Expense2.963.414.373.003.073.032.985.55
Unusual Expense0.000.000.000.070.000.00-0.360.14
Net Income Before Taxes9.0015.14-11.2017.867.49-15.54-24.78-10.46
Income Taxes0.200.140.090.470.080.340.280.32
Consolidated Net Income8.8015.01-11.2917.397.41-15.89-25.06-10.79
Net Income From Continuing Operations8.8015.01-11.2917.397.41-15.89-25.06-10.79
Net Income8.8015.01-11.2917.397.41-15.89-25.06-10.79
EPS (Recurring)0.060.11-0.090.130.06-0.13-0.20-0.09
EPS (Basic, Before Extraordinaries)0.070.12-0.090.140.06-0.13-0.20-0.09
EPS (Diluted)0.060.11-0.090.130.06-0.13-0.20-0.09
EBITDA10.0016.99-8.5319.659.09-14.05-21.40-7.17
Non-Operating Income (Expense)2.522.122.252.552.042.102.372.86
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.7610.088.457.957.938.297.727.42
Price To Earnings Ratio126.96-------
Price To Sales Ratio7.117.687.3310.477.886.769.268.85
Gross Margin91.3491.5890.7290.9791.2590.8186.5990.32
Operating Margin6.5612.65-8.6214.208.59-17.93-37.25-10.70
Net Margin6.1211.56-10.7213.437.47-19.49-38.06-15.12
Shares Outstanding126.02125.59125.04123.33120.29119.80119.14117.85
Market Capitalization3,462.973,279.682,922.223,557.172,260.211,671.211,855.501,630.44

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments221.29228.57272.79410.82388.60285.98101.2750.943.42
Short Term Receivables146.2373.0725.818.460.360.510.000.000.00
Inventories22.6314.5313.137.510.000.000.000.000.00
Other Current Assets21.0819.6618.7010.6113.816.333.460.160.40
Total Current Assets411.23335.82330.43437.41402.77292.83104.7351.103.82
Net Property, Plant & Equipment5.512.993.904.605.305.370.490.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets14.819.486.447.19---0.000.00
Other Assets1.420.600.600.080.080.081.790.000.00
Total Assets432.97348.89341.37449.27408.15298.27107.0151.103.82
Short Term Debt Incl. Current Port. of LT Debt1.000.820.730.660.430.000.180.000.00
Accounts Payable12.5314.2211.998.837.357.141.411.800.54
Other Current Liabilities116.3165.9733.9428.3225.5415.463.650.870.15
Total Current Liabilities129.8481.0146.6737.8133.3322.605.242.670.69
Long Term Debt113.22109.77205.18201.8977.124.960.130.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.430.570.850.000.030.080.180.160.97
Total Liabilities243.49191.35252.70239.69110.4727.655.552.831.66
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00166.4972.257.15
Common Equity189.48157.5488.67209.58297.68270.62-65.03-23.99-4.99
Total Shareholders Equity189.48157.5488.67209.58297.68270.62101.4648.272.16
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity189.48157.5488.67209.58297.68270.62101.4648.272.16
Total Liabilities & Stockholders Equity432.97348.89341.37449.27408.15298.27107.0151.103.82
Book Value Per Share1.541.340.923.435.926.24-1.71-0.66-0.14
Tangible Book Value Per Share1.421.260.853.325.926.24-1.71-0.66-0.14
Full-Time Employees3543422962681475429--
Price to Book Ratio14.1510.404.283.333.504.506.40--
Return on Assets-4.13-40.58-66.31-72.65-58.42-66.96-53.12-70.12-
Return on Equity-9.30-113.76-175.79-122.80-72.62-72.93-56.10-76.37-
Return on Invested Capital-5.33-52.39-89.21-75.69-55.06-49.23-41.34-39.89-230.36
Quick Ratio2.993.976.8011.3712.0912.9620.0019.125.52
Current Ratio3.174.157.0811.5712.0912.9620.0019.125.52

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income29.91-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.25
Depreciation2.254.672.601.881.250.760.460.20-
Other Funds (Non Cash)48.0040.6840.3636.7062.6627.358.06-0.933.06
Funds from Operations80.1629.20-97.08-223.56-247.54-178.25-127.17-42.73-16.19
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-20.20-34.83-15.08-23.50-10.183.6214.13-1.502.11
Cash from Operating Activities59.96-5.62-112.16-247.06-257.71-174.63-113.03-44.24-14.09
Capital Expenditures-0.26-10.69-5.14-0.43-7.83-0.99-0.32-0.290.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-82.56-19.5733.96180.66-63.92-74.96-181.50-26.03-11.53
Purchase of Investments-288.28-246.99-254.82-225.84-415.39-292.51-279.10-60.83-11.53
Sale Or Maturity of Investments205.71227.42288.78406.50351.47217.5597.6034.800.00
Other Uses0.000.000.000.00-15.450.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-82.82-30.2528.82180.23-87.20-75.95-181.82-26.32-11.53
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.236.97166.20101.32178.99209.60298.1494.5061.59
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.236.97166.20101.32178.99209.60298.1494.5061.59
Proceedsfrom Stock Options2.692.38163.40100.08177.97208.33297.6294.2461.21
Issuance or Reduction of Debt, Net0.000.00-100.000.00122.8172.350.000.000.00
Change in Long Term Debt0.000.00-100.000.00122.8172.350.000.000.00
Issuance of Long Term Debt0.000.000.000.00122.8172.350.000.000.00
Reduction of Long Term Debt0.000.00-100.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses-1.000.000.000.000.000.000.000.000.00
Cash from Financing Activities9.236.9766.20101.32301.80281.95298.1494.5061.59
Exchange Rate Effect-0.120.17-0.23-0.05-----
Net Change in Cash-13.75-28.74-17.3734.45-43.1231.373.2923.9435.98
Free Cash Flow59.71-6.31-112.30-247.49-258.05-175.62-113.35-44.53-14.09
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Price to Free Cash Flow60.57--------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments259.77238.86224.31221.29191.38191.13
Short Term Receivables171.28155.16144.38146.23115.12106.69
Inventories45.6738.8837.3922.6322.4216.32
Other Current Assets26.9734.7731.9821.0820.3118.64
Total Current Assets503.69467.67438.06411.23349.22332.78
Net Property, Plant & Equipment4.945.125.405.515.783.12
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets13.1213.6914.2514.8115.3815.94
Other Assets2.672.052.301.420.600.60
Total Assets524.43488.54460.00432.97370.98352.43
Short Term Debt Incl. Current Port. of LT Debt16.156.957.951.001.001.00
Accounts Payable8.346.6018.3012.535.7915.08
Other Current Liabilities147.87146.79136.96116.3192.9787.85
Total Current Liabilities172.36160.34163.20129.8499.77103.94
Long Term Debt107.67107.19106.72113.22112.77109.16
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.430.430.430.430.360.36
Total Liabilities280.46267.96270.36243.49212.90213.46
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity243.97220.58189.65189.48158.07138.97
Total Shareholders Equity243.97220.58189.65189.48158.07138.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity243.97220.58189.65189.48158.07138.97
Total Liabilities & Stockholders Equity524.43488.54460.00432.97370.98352.43
Book Value Per Share1.941.761.521.541.311.16
Tangible Book Value Per Share1.831.651.401.421.191.03
Full-Time Employees---354--
Price to Book Ratio14.1517.2915.3422.1016.2511.71
Return on Assets6.686.78-0.59-4.13-10.97-23.40
Return on Equity14.8815.86-1.43-9.30-28.17-57.33
Return on Invested Capital2.504.58-3.815.752.74-6.40
Quick Ratio2.662.672.462.993.283.04
Current Ratio2.922.922.683.173.503.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income8.8015.01-11.2917.397.41-15.89
Depreciation0.560.560.560.560.560.41
Other Funds (Non Cash)12.9713.3011.1810.5510.2210.67
Funds from Operations22.3328.870.4528.5118.19-4.80
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.44-16.231.79-2.33-19.945.13
Cash from Operating Activities18.9012.642.2426.18-1.750.32
Capital Expenditures-0.10-0.160.000.000.00-10.08
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-21.99-15.07-11.33-34.18-25.2527.50
Purchase of Investments-71.35-65.59-62.15-89.18-68.54-33.15
Sale Or Maturity of Investments49.3750.5250.8255.0043.3060.65
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-22.08-15.22-11.33-34.18-25.2517.42
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.452.991.073.721.481.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.452.991.073.721.481.38
Proceedsfrom Stock Options0.001.630.001.060.001.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-1.000.000.000.000.00
Other Financing Activities Uses0.00-1.000.000.000.000.00
Cash from Financing Activities2.451.991.073.721.481.38
Exchange Rate Effect-0.01-0.05-0.120.06-0.100.20
Net Change in Cash-0.75-0.64-8.14-4.21-25.6219.33
Free Cash Flow18.8012.482.2426.18-1.750.25
Price to Free Cash Flow60.5791.01113.24---

Revenue breakdown

ZORYVE Cream 0.3%2024: 85.08M 2025: 121.00M
ZORYVE Cream 0.5%2024: 9.92M 2025: 68.27M
ZORYVE Foam2024: 71.54M 2025: 181.89M
ZORYVE cream 0.05%2025: 911.00K
United States2024: 166.54M 2025: 372.07M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.48%18.2M110.2M2.49M
2026-10-1518.71%20.5M109.5M2.28M
2026-09-3019.81%21.7M109.5M2.18M
2026-09-1516.86%18.5M109.5M1.77M
2026-08-3115.12%16.6M109.5M1.67M
2026-08-1413.45%14.7M109.4M1.69M
2026-07-3111.46%12.7M110.7M1.80M
2026-07-1512.31%13.6M110.2M1.78M
2026-06-3012.70%14.0M110.4M1.72M
2026-06-1514.29%15.8M110.7M1.60M
2026-05-2914.69%16.2M110.4M1.54M
2026-05-1515.89%17.5M110.4M1.51M
2026-04-3015.30%16.9M110.4M1.29M
2026-04-1515.17%16.6M109.4M1.31M
2026-03-3115.37%16.8M109.3M1.44M
2026-03-1314.41%15.8M109.3M1.52M
2026-02-2713.99%15.3M109.3M1.63M
2026-02-1315.17%16.4M108.0M1.84M
2026-01-3014.86%16.0M107.7M2.03M
2026-01-1514.14%15.2M107.6M2.32M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5013.5018.000.007.2580.000.000.965-0.0640.003
call15.0011.0015.5014.215.9821.000.000.899-0.1870.008
call17.508.5013.000.004.9360.000.000.874-0.1770.009
call20.006.0010.5012.003.9561.000.000.843-0.1650.011
call22.503.508.303.302.9451.000.000.806-0.1500.012
call25.001.004.902.471.6513.000.000.744-0.1280.014
call27.500.002.201.471.0562,0172.000.597-0.2140.017
call30.000.100.550.400.68978.001.000.365-0.0880.017
call32.500.000.450.381.0521440.000.221-0.0770.013
call35.000.000.900.031.27145.000.000.164-0.0780.011
call37.500.004.900.051.55414.000.000.154-0.0910.011
call40.000.001.500.001.6140.000.000.098-0.0640.008
call45.000.004.400.652.1291.000.000.112-0.1000.008
put12.500.000.250.007.1990.000.00-0.105-0.2980.008
put15.000.004.900.004.2870.000.00-0.100-0.1850.008
put17.500.004.900.003.4710.000.00-0.126-0.1750.009
put20.000.004.900.052.7801.000.00-0.156-0.1630.011
put22.500.004.900.002.1550.000.00-0.197-0.1460.012
put25.000.001.251.052.4104.000.00-0.333-0.1970.016
put27.500.104.802.302.96520.000.00-0.403-0.2110.017
put30.000.504.903.002.19353.000.00-0.620-0.0880.017
put32.502.556.507.002.10138.000.00-0.801-0.0640.012
put35.005.009.009.102.4730.000.00-0.836-0.0740.011
put37.507.5011.500.002.7930.000.00-0.857-0.0810.010
put40.0010.1014.000.003.0750.000.00-0.870-0.0870.009
put45.0015.1019.000.003.5580.000.00-0.888-0.0950.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-04SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-043/A2026-10-23SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-04424B5SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-283Initial statement of beneficial ownership of securities2026-10-23SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-288-KCurrent report2026-10-23SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05SCHEDULE 13G/ASEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.58M4
2026-1000127.33K1
2026-0900456.21K3
2026-08001.72M9
2026-0700127.28K1
2026-0600236.87K3
2026-0500493.17K7
2026-0400238.80K1
2026-03002.74M7
2026-02002.31M8
2026-0100361.77K2
2025-1200734.64K4
2025-11005.79M14

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC9.94%
BlackRock, Inc.8.43%
Frazier Life Sciences Management, L.P.7.89%
Rubric Capital Management LP6.61%
Polar Capital Holdings Plc5.28%
STATE STREET CORP4.66%
UBS Group AG4.40%
VANGUARD CAPITAL MANAGEMENT LLC3.99%
MORGAN STANLEY3.56%
JENNISON ASSOCIATES LLC3.37%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
iShares Russell 2000 ETF2.35%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.33%
Small Cap Growth Fund1.17%
PGIM Jennison Small Company Fund1.11%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
Fidelity Small Cap Index Fund1.00%
Oberweis Small-Cap Opportunities Fund0.97%
iShares Russell 2000 Growth ETF0.84%
BARON DISCOVERY FUND0.69%

OakChart. ARQT. Cached 15 minutes.